Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

US Food and Drug Administration grants accelerated approval for Alzheimer's drug

The drug, developed under the name Leqembi by U.S. company Biogen in collaboration with Japanese pharmaceutical company Eisai, has been evaluated in series of tests involving 856 Alzheimer's patients, the FDA announced January 6. It said patients treated with Leqembi had significantly better outcomes than a placebo group. Eisai and Biogen stress in the drug's description that it is only suitable for mild and early cases of the disease. The company also plans to file for marketing approval in Japan and Europe by the end of March 2023. So what is the market potential and do these results herald a new era in Alzheimer's research?
09.01.2023 - Christian Lach, Lukas Leu
FDA grants accelerated approval for Alzheimer's drug